Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Earnings for Novo Nordisk A/S (NVO)
Earnings in 2023 (TTM): $104.67 B
According to Novo Nordisk A/S's latest financial reports the company's current earnings (TTM) are $104.67 B. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Novo Nordisk A/S
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $104.67 B | $83.68 B |
| 2022 | $69.06 B | $55.53 B |
| 2021 | $59.08 B | $47.76 B |
| 2020 | $53.13 B | $42.14 B |
| 2019 | $48.55 B | $38.95 B |
| 2018 | $47.62 B | $38.63 B |
| 2017 | $48.68 B | $38.13 B |
| 2016 | $47.8 B | $37.93 B |
| 2015 | $43.48 B | $34.86 B |
| 2014 | $34.1 B | $26.48 B |
| 2013 | $32.54 B | $25.18 B |
| 2012 | $27.81 B | $21.43 B |
| 2011 | $21.93 B | $17.1 B |
| 2010 | $18.29 B | $14.4 B |
| 2009 | $13.99 B | $10.77 B |
| 2008 | $12.73 B | $9.67 B |
| 2007 | $10.98 B | $8.54 B |
| 2006 | $9.17 B | $6.45 B |
| 2005 | $8.22 B | $5.86 B |
| 2004 | $7.51 B | $5.05 B |
| 2003 | $7.58 B | $4.87 B |
| 2002 | $6.29 B | $4.09 B |
| 2001 | $6.01 B | $3.85 B |
| 2000 | $4.84 B | $3.09 B |
| 1999 | $3.96 B | $2.41 B |
| 1998 | $3.75 B | $2.41 B |
| 1997 | $3.17 B | $2.22 B |
| 1996 | $2.53 B | $1.8 B |
| 1995 | $2.15 B | $1.56 B |
| 1994 | $1.93 B | $1.43 B |
| 1993 | $1.87 B | $1.43 B |
| 1992 | $1.67 B | $1.27 B |
| 1991 | $1.46 B | $930.19 M |
| 1990 | $1.14 B | $760.12 M |
| 1989 | $1.05 B | $745.99 M |
| 1988 | $905.31 M | $637.91 M |
| 1987 | $697.44 M | $480.4 M |
| 1986 | $788.58 M | $521.32 M |
| 1985 | $876.68 M | $607.76 M |